# List Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/list-biotherapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.list-bio.com
- Total disclosed funding: $31M
- Latest round: Series A (Dec 1, 2021)
- Investors on record: 5

## About

Founded in 2021 and based in Indiana, US, List Biotherapeutics Inc is a CDMO with expertise in early-stage clinical trial development and cGMP manufacturing. List Biotherapeutics Inc is a wholly-owned subsidiary of Genome and Co., as well as a sister company to List Labs (List Biological Laboratories). In March 2022, List Biotherapeutics Inc USD 17.4 million in venture funding from Paratus Investment, and SV Investment. Jonathan Yongwan Jo is the president and CEO of the company.

The company offers CMO services for late-stage clinical trials and commercialization of Live Biotherapeutics derived from beneficial bacteria. 

The organization plans to use the March 2022 funding to build a new large-scale microbiome production facility in Fishers, US, and start the microbiome CDMO business.

## Funding rounds

- Series A, Dec 1, 2021, $31M — Korea Investment & Securities, Korea Investment Partners, DSC Investment, Hana Ventures, Daewon Pharmaceuticals

## Investors

- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Hana Ventures — Series A
- Daewon Pharmaceuticals — Series A